Sep 14, 2017 4:05pm EDT Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
Sep 6, 2017 7:00am EDT Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Aug 29, 2017 4:30pm EDT Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
Aug 21, 2017 7:00am EDT Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium
Aug 14, 2017 7:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update
Jul 6, 2017 7:00am EDT Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
Jun 15, 2017 7:00am EDT Tonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored by U.S. Department of Defense
Jun 12, 2017 7:00am EDT Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference